Therapeutic applications of NSAIDS in cancer: Special emphasis on tolfenamic acid

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 2, 2011, Pages 797-805

  Basha, Riyaz ^a,b   Baker, C T ^a,c   Sankpal, Umesh T ^a   Ahmad, Sarfraz ^b,d   Safe, Stephen ^e   Abbruzzese, James L ^f   Abdelrahim, Maen ^a,b,c  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^d FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Lung Cancer; NSAID; Pancreatic Cancer; Review; Sp1; Sp3; Tolfenamic Acid; Transcription Factors

Indexed keywords

ACEMETACIN; ACETIC ACID DERIVATIVE; ACETYLSALICYLIC ACID; AMPIROXICAM; CELECOXIB; DICLOFENAC; DIFLUNISAL; FENBUFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; SURVIVIN; TOLFENAMIC ACID; TOLMETIN; TRANSCRIPTION FACTOR SP; ANTHRANILIC ACID DERIVATIVE;

ANALGESIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DIVISION; CELL PROLIFERATION; CELL VIABILITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG CANCER; NEOPLASM; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIZATION; ANIMAL; METABOLISM; MOUSE; RADIATION DOSE; REVIEW;

ANIMALIA;

ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL PROLIFERATION; HUMANS; MICE; NEOPLASMS; RADIATION TOLERANCE; SP TRANSCRIPTION FACTORS;

EID: 79955954938     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. R. N. Dubois, S. B. Abramson, L. Crofford, R. A. Gupta, L. S. Simon, L. B. Van De Putte and P. E. Lipsky: Cyclooxygenase in biology and disease. FASEB J, 12(12), 1063-73 (1998) (Pubitemid 28418937)
2. J. R. Vane: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 231(25), 232-5 (1971)
3. C. S. Williams, M. Mann and R. N. DuBois: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18(55), 7908-16 (1999) (Pubitemid 30066236)
4. J. L. Mehta: Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. Clin Cardiol, 21(12), 879-84 (1998) (Pubitemid 28559693)
5. K. J. Mukamal, M. A. Mittleman, M. Maclure, J. B. Sherwood, R. J. Goldberg and J. E. Muller: Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction. Am Heart J, 137(6), 1120-8 (1999) (Pubitemid 30040738)
6. H. C. Diener: Aspirin in the prevention of strokes. Biomed Pharmacother, 53(7), 309-11 (1999)
7. L. A. Garcia Rodriguez, C. Varas and C. Patrono: Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology, 11(4), 382-7 (2000) (Pubitemid 30428929)
8. D. L. DeWitt: Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol, 55(4), 625-31 (1999)
9. N. Futaki, K. Yoshikawa, Y. Hamasaka, I. Arai, S. Higuchi, H. Iizuka and S. Otomo: NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol, 24(1), 105-10 (1993) (Pubitemid 23089182)
10. R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. McDonald, R. A. Stegeman, J. Y. Pak, D. Gildehaus, J. M. Miyashiro, T. D. Penning, K. Seibert, P. C. Isakson and W. C. Stallings: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 384(6610), 644-8 (1996)
11. J. L. Masferrer, B. S. Zweifel, P. T. Manning, S. D. Hauser, K. M. Leahy, W. G. Smith, P. C. Isakson and K. Seibert: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A, 91(8), 3228-32 (1994) (Pubitemid 24130209)
12. M. P. Flattery and L. A. Hylton Gravatt: COX-2 inhibitors and cardiovascular risk. Prog Cardiovasc Nurs, 20(3), 123-5 (2005)
13. S. F. Jones and I. Power: Postoperative NSAIDs and COX-2 in hibitors: cardiovascular risks and benefits. Br J Anaesth, 95(3), 281-4 (2005) (Pubitemid 41487335)
14. E. M. Antman, D. DeMets and J. Loscalzo: Cyclooxygenase inhibition and cardiovascular risk. Circulation, 112(5), 759-70 (2005) (Pubitemid 41099056)
15. S. J. Baek, K. S. Kim, J. B. Nixon, L. C. Wilson and T. E. Eling: Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol, 59(4), 901-8 (2001) (Pubitemid 32274020)
16. R. Hanif, A. Pittas, Y. Feng, M. I. Koutsos, L. Qiao, L. Staiano-Coico, S. I. Shiff and B. Rigas: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol, 52(2), 237-45 (1996) (Pubitemid 26233752)
17. E. Kopp and S. Ghosh: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science, 265(5174), 956-9 (1994)
18. B. K. Law, M. E. Waltner-Law, A. J. Entingh, A. Chytil, M. E. Aakre, P. Norgaard and H. L. Moses: Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J Biol Chem, 275(49), 38261-7 (2000) (Pubitemid 32009146)
19. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold and S. A. Kliew er: Peroxisome proliferatoractivated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem, 272(6), 3406-10 (1997)
20. Peleg, II, M. F. Lubin, G. A. Cotsonis, W. S. Clark and C. M. Wilcox: Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci, 41(7), 1319-26 (1996) (Pubitemid 26245910)
21. G. Steinbach, P. M. Lynch, R. K. Phillips, M. H. Wallace, E. Hawk, G. B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L. K. Su and B. Levin: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 342(26), 1946-52 (2000) (Pubitemid 30419089)
22. K. P. Nugent, K. C. Farmer, A. D. Spigelman, C. B. Williams and R. K. Phillips: Rand omized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg, 80(12), 1618-9 (1993) (Pubitemid 24007679)
23. S. K. Boolbol, A. J. Dannenberg, A. Chadburn, C. Martucci, X. J. Guo, J. T. Ramonetti, M. Abreu-Goris, H. L. Newmark, M. L. Lipkin, J. J. DeCosse and M. M. Bertagnolli: Cyclooxygenase-2 overexpression and tumor formation are b locked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res, 56(11), 2556-60 (1996) (Pubitemid 26171681)
24. R. F. Jacoby, K. Seibert, C. E. Cole, G. Kelloff and R. A. Lubet: The cyclo oxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res, 60(18), 5040-4 (2000)
25. B. S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K. Seibert and C. V. Rao: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res, 60(2), 293-7 (2000) (Pubitemid 30070754)
26. S. Gately and W. W. Li: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol, 31(2 Suppl 7), 2-11 (2004)] (Pubitemid 38879409)
27. A. S. Tarnawski and M. K. Jones: Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J Mol Med, 81(10), 627-36 (2003) (Pubitemid 37357677)
28. E. L. Barry, L. B. Sansbury, M. V. Grau, I. U. Ali, S. Tsang, D. J. Munroe, D. J. Ahnen, R. S. Sandler, F. Saibil, J. Gui, R. S. Bresalier, G. E. McKeown-Eyssen, C. Burke and J. A. Baron: Cyclooxygenase-2 polymorphisms, a spirin treatment, and risk for colorectal adenoma recurrence - data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev, 18(10), 2726-33 (2009)
29. K. K. Wu and J. Y. Liou: Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPARdelta - > 14-3-3epsilon pathway. Methods Mol Biol, 512, 295-307 (2009)
30. P. C. Elwood, A. M. Gallagher, G. G. Duthie, L. A. Mur and G. Morgan: Aspirin, salicylates, and cancer. Lancet, 373(9671), 1301-9 (2009)
31. M. M. Taketo: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst, 90(21), 1609-20 (1998) (Pubitemid 28523435)
32. J. Colon, M. R. Basha, R. Madero-Visbal, S. Konduri, C. H. Baker, L. J. Herrera, S. Safe, D. Sheikh-Hamad, A. Abudayyeh, B. Alvarado and M. Ab delrahim: Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs (2009)
33. R. Klan, H. H. Knispel and T. Meier: Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl)nitrosamineinduced bladder carcinogenesis in rats. J Cancer Res Clin Oncol, 119(8), 482-5 (1993) (Pubitemid 23165055)
34. N. Kundu and A. M. Fulton: Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res, 62(8), 2343-6 (2002) (Pubitemid 34411715)
35. G. Murasaki, T. V. Zenser, B. B. Davis and S. M. Cohen: Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2- thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis, 5(1), 53-5 (1984) (Pubitemid 14197926)
36. S. Papineni, S. Chintharlapalli, M. Abdelrahim, S. O. Lee, R. Burghardt, A. Abudayyeh, C. Baker, L. Herrera and S. Safe: Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcin ogenesis, 30(7), 1193-201 (2009)
37. K. V. Rao, C. J. Detrisac, V. E. Steele, E. T. Hawk, G. J. Kelloff and D. L. McCormick: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17(7), 1435-8 (1996) (Pubitemid 26242647)
38. M. Takahashi, F. Furukawa, K. Toyoda, H. Sato, R. Hasegawa, K. Imaida and Y. Hayashi: Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with Nnitrosobis( 2-oxopropyl)amine. Carcinogenesis, 11(3), 393-5 (1990) (Pubitemid 20079390)
39. D. Gidoni, W. S. Dynan and R. Tjian: Multiple specific contacts between a mammalian transcription factor and its cognate promoters. Nature, 312(5993), 409-13 (1984) (Pubitemid 15217832)
40. G. Suske: The Sp-family of transcription factors. Gene, 238(2), 291-300 (1999) (Pubitemid 29446168)
41. J. Cui, X. Meng, X. Gao and G. Tan: Curcumin decreases the expression of Pokemon by suppressing the binding activity of the Sp1 protein in human lung cancer cells. Mol Biol Rep (2009)
42. M. Abdelrahim, C. H. Baker, J. L. Abbruzzese and S. Safe: Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst, 98(12), 855-68 (2006) (Pubitemid 43923442)
43. S. Konduri, J. Colon, C. H. Baker, S. Safe, J. L. Abbruzzese, A. Abudayyeh, M. R. Basha and M. Abdelrahim: Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther, 8(3), 533-42 (2009)
44. Z. Jia, Y. Gao, L. Wang, Q. Li, J. Zhang, X. Le, D. Wei, J. C. Yao, D. Z. Chang, S. Huang and K. Xie: Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res, 70(3), 1111-9
45. D. C. Altieri: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med, 7(12), 542-7 (2001) (Pubitemid 33127139)
46. G. Ambrosini, C. Adida and D. C. Altieri: A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3(8), 917-21 (1997) (Pubitemid 27353455)
47. C. Adida, D. Berrebi, M. Peuchmaur, M. Reyes-Mugica and D. C. Al tieri: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet, 351(9106), 882-3 (1998) (Pubitemid 28121185)
48. K. Satoh, K. Kaneko, M. Hirota, A. Masamune, A. Satoh and T. Shimosegawa: Ex pression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer, 92(2), 271-8 (2001) (Pubitemid 32664432)
49. A. I. Sarela, C. S. Verbeke, J. Ramsdale, C. L. Davies, A. F. Markham and P. J. Guillou: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer, 86(6), 886-92 (2002) (Pubitemid 34271023)
50. K. Kami, R. Doi, M. Koizumi, E. Toyoda, T. Mori, D. Ito, K. Fujimoto, M. Wada, S. Miyatake and M. Imamura: Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery, 136(2), 443-8 (2004) (Pubitemid 39037686)
51. F Li, D C Altieri: Transcriptional analysis of human survivin gene expression. Biochem J, 344 Pt 2, 305-11 (1999) (Pubitemid 30011584)
52. Y Li, M Xie, J Yang, D Yang, R Deng, Y Wan, B. Yan: The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal pro moter. Oncogene, 25(23), 3296-306 (2006) (Pubitemid 43846314)
53. J Wu, X Ling, D Pan, P Apontes, L Song, P Liang, D C Altieri, T Beerman, F Li: Molecular mechanism of inhibition of survivin t ranscription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem, 280(10), 9745-51 (2005) (Pubitemid 40409673)
54. S Chinth arlapalli, S Papineni, S K Ramaiah, S Safe: Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res, 67(6), 2816-23 (2007) (Pubitemid 46548971)
55. J C Yao, L Wang, D Wei, W Gong, M Hassan, T T Wu, P Mansfield, J Ajani, K Xie: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res, 10(12 Pt 1), 4109-17 (2004) (Pubitemid 38812490)
56. L Wang, D Wei, S Huang, Z Peng, X Le, T T Wu, J Yao, J Ajani, K Xie: T ranscription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res, 9(17), 6371-80 (2003) (Pubitemid 38031822)
57. A Zannetti, S Del Vecchio, M V Carriero, R Fonti, P Franco, G Botti, G D'Aiuto, M P Stoppelli, M Salvatore: Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res, 60(6), 1546-51 (2000) (Pubitemid 30183423)
58. E Chiefari, A Brunetti, F Arturi, J M. Bidart, D Russo, M Schlumberger, S Filetti: Increased expression of AP2 and Sp1 tran scription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer, 2, 35 (2002)
59. Y Hosoi, T Watanabe, K Nakagawa, Y Matsumoto, A Enomoto, A Morita, H Nagawa, N S uzuki: Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol, 25(2), 461-8 (2004)
60. H Zhong, J P Bowen: Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr Med Chem, 13(8), 849-62 (2006)
61. M Abdelrahim, C.H Baker, J L Abbruzzese, D Sheikh- Hamad, S Liu, S D Cho, K Yoon, S Safe: Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res, 67(7), 3286-94 (2007) (Pubitemid 46724867)
62. P Bouwman, S Philipsen: Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol, 195(1- 2), 27-38 (2002) (Pubitemid 35287159)
63. S Safe, K Kim: Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol, 77, 1-36 (2004)
64. Q Shi, X Le, J L Abbruzzese, Z Peng, C N. Qian, H Tang, Q Xiong, B Wang, X C Li, K Xie: Constitutive Sp1 activity is essenti al for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res, 61(10), 4143-54 (2001) (Pubitemid 32720983)